共 98 条
[1]
Hammond ME(2010)American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol Off J Am Soc Clin Oncol 28 2784-2795
[2]
Hayes DF(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol Off J Am Soc Clin Oncol 25 118-145
[3]
Dowsett M(2009)The epidemiology of triple-negative breast cancer, including race Cancer Causes Control: CCC 20 1071-1082
[4]
Allred DC(2012)Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network Cancer 118 5463-5472
[5]
Hagerty KL(2006)Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658-1667
[6]
Badve S(2014)Platinum-based chemotherapy in triple-negative advanced breast cancer Breast Cancer Res Treat 146 567-572
[7]
Wolff AC(2014)Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression Oncol Lett 7 866-870
[8]
Hammond ME(2009)Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clinical Breast Cancer 9 29-33
[9]
Schwartz JN(2010)Chemotherapy: dose-dense treatment for triple-negative breast cancer Nat Rev Clin Oncol 7 79-80
[10]
Hagerty KL(2014)Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Lancet Oncology 15 747-756